Champions Financial Statements From 2010 to 2024
CSBR Stock | USD 5.07 0.04 0.80% |
Gross Profit 24.3 M | Profit Margin (0.20) | Market Capitalization 71 M | Enterprise Value Revenue 1.4473 | Revenue 49.2 M |
Champions Oncology Total Revenue |
|
Check Champions Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Champions main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.7 M, Interest Expense of 38.3 K or Selling General Administrative of 12.4 M, as well as many exotic indicators such as Price To Sales Ratio of 1.33, Dividend Yield of 0.0033 or PTB Ratio of 17.14. Champions financial statements analysis is a perfect complement when working with Champions Oncology Valuation or Volatility modules.
Champions | Select Account or Indicator |
Champions Oncology Balance Sheet | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Champions Oncology Income Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Champions Oncology Cash Flow Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Ratios | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Champions Oncology Valuation Data | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Champions Fundamental Market Drivers
Forward Price Earnings | 22.8833 | |
Cash And Short Term Investments | 10.1 M |
Champions Upcoming Events
20th of March 2024 Upcoming Quarterly Report | View | |
22nd of July 2024 Next Financial Report | View | |
31st of January 2024 Next Fiscal Quarter End | View | |
22nd of July 2024 Next Fiscal Year End | View | |
31st of October 2023 Last Quarter Report | View | |
30th of April 2023 Last Financial Announcement | View |
About Champions Oncology Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Champions Oncology income statement, its balance sheet, and the statement of cash flows. Champions Oncology investors use historical funamental indicators, such as Champions Oncology's revenue or net income, to determine how well the company is positioned to perform in the future. Although Champions Oncology investors may use each financial statement separately, they are all related. The changes in Champions Oncology's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Champions Oncology's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Champions Oncology Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Champions Oncology. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Current Deferred Revenue | 14.7 M | 15.4 M | |
Total Revenue | 62 M | 65 M | |
Cost Of Revenue | 34 M | 35.7 M | |
Stock Based Compensation To Revenue | 0.02 | 0.02 | |
Sales General And Administrative To Revenue | 0.22 | 0.43 | |
Research And Ddevelopement To Revenue | 0.25 | 0.33 | |
Capex To Revenue | (0.06) | (0.06) | |
Revenue Per Share | 4.57 | 2.66 | |
Ebit Per Revenue | (0.1) | (0.1) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Champions Oncology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Champions Oncology's short interest history, or implied volatility extrapolated from Champions Oncology options trading.
Pair Trading with Champions Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Champions Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will appreciate offsetting losses from the drop in the long position's value.Moving together with Champions Stock
0.84 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
0.74 | ME | 23Andme Holding | PairCorr |
Moving against Champions Stock
0.8 | VCEL | Vericel Corp Ord Financial Report 8th of May 2024 | PairCorr |
0.79 | DNTH | Dianthus Therapeutics Symbol Change | PairCorr |
0.74 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
0.74 | YS | YS Biopharma Report 22nd of April 2024 | PairCorr |
0.63 | VERA | Vera Therapeutics Downward Rally | PairCorr |
The ability to find closely correlated positions to Champions Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Champions Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Champions Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Champions Oncology to buy it.
The correlation of Champions Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Champions Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Champions Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Champions Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Champions Oncology Correlation against competitors. To learn how to invest in Champions Stock, please use our How to Invest in Champions Oncology guide.Note that the Champions Oncology information on this page should be used as a complementary analysis to other Champions Oncology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Champions Stock analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is Champions Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Champions Oncology. If investors know Champions will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Champions Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.29) | Earnings Share (0.72) | Revenue Per Share 3.634 | Quarterly Revenue Growth (0.06) | Return On Assets (0.17) |
The market value of Champions Oncology is measured differently than its book value, which is the value of Champions that is recorded on the company's balance sheet. Investors also form their own opinion of Champions Oncology's value that differs from its market value or its book value, called intrinsic value, which is Champions Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Champions Oncology's market value can be influenced by many factors that don't directly affect Champions Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Champions Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Champions Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Champions Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.